Paratek Pharmaceuticals (PRTK): Omadacycline Hits Primary Endpoints - Cantor
Tweet Send to a Friend
Cantor Fitzgerald analyst, Chiara Russo, reiterated her Overweight rating on shares of Paratek Pharmaceuticals (NASDAQ: PRTK) after the news that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


